	US 12,251,374 B2
	Fampridine TTS
Rosemarie Keikert, Andernach (DE)
Assigned to LTS Lohmann Therapie-Systeme AG, Andernach (DE)
Appl. No. 16/629,608
Filed by LTS Lohmann Therapie-Systeme AG, Andernach (DE)
PCT Filed Jul. 12, 2018, PCT No. PCT/EP2018/068952 § 371(c)(1), (2) Date Jan. 9, 2020, PCT Pub. No. WO2019/012047, PCT Pub. Date Jan. 17, 2019.
Claims priority of application No. 10 2017 115 701.8 (DE), filed on Jul. 12, 2017.
Prior Publication US 2020/0237682 A1, Jul. 30, 2020
Int. Cl. A61K 9/70 (2006.01); A61K 31/4409 (2006.01)

CPC A61K 31/4409 (2013.01) [A61K 9/7069 (2013.01)]

16 Claims

1. A transdermal therapeutic system for cutaneous administration of fampridine comprising an active ingredient-impermeable backing layer, a pressure-sensitive adhesive reservoir layer and optionally a detachable protective layer, wherein the pressure-sensitive adhesive layer contains fampridine and at least one matrix polymer, wherein the matrix polymer(s) contain no carboxylic acid and/or carboxylate groups, and wherein the content of fampridine in the matrix polymer is <5% by weight and

wherein the size of the transdermal therapeutic system is in the range of from 5 to 20 cm²,

the matrix polymer(s) ensures continuous skin-contact

wherein the fampridine has been dissolved in toluene or ethyl acetate, and the system does not include a tackifier.